logo
  

Amgen To Present Lumakras Combination Data From Phase 1b Study On KRAS G12C-mutated Cancers

Amgen (AMGN) announced new combination study results from the Phase 1b CodeBreaK 101 study, a comprehensive global master protocol trial evaluating the safety and efficacy of Lumakras (sotorasib) in more than 10 different investigational combination regimens for the treatment of patients with KRAS G12C-mutated cancers.

The company will present results from two arms of the study — Lumakras with afatinib, a pan-ErbB tyrosine kinase inhibitor, and LUMAKRAS with trametinib, a mitogen-activated protein kinase inhibitor (MEKi) — at the plenary session titled 'Drugging Difficult Targets' during the AACR-NCI-EORTC 2021 Virtual International Conference on Molecular Targets and Cancer Therapeutics on October 9, 2021.

The Lumakras and afatinib combination arm enrolled 33 heavily pre-treated patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), including five patients previously treated with LUMAKRAS monotherapy.

Ten patients received 20 mg of afatinib/960 mg of sotorasib and 23 patients received 30 mg of afatinib/960 mg of sotorasib. The objective response rate (ORR) was 20% in cohort 1 and 35% in cohort 2, and the disease control rate was 70% and 74% in the two cohorts, respectively.

In CodeBreaK 101, the combination of Lumakras and trametinib showed antitumor activity in heavily pre-treated patients with KRAS G12C-mutated solid tumors, including those with prior KRASG12C inhibitor treatment.

Lumakras is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Aerospace giant Boeing Co. (BA) on Wednesday reported fourth-quarter net loss attributable to Boeing shareholders of $4.16 billion or $7.02 per share, sharply narrower than $8.44 billion or $14.65 per share in the year-ago quarter. The 787 program recorded $3.5 billion pre-tax non-cash charge; focused... Telecom giant AT&T reported Wednesday a profit for the fourth quarter compared to a loss last year, primarily boosted by continuing customer growth in wireless, fiber and HBO Max, despite a 10 percent drop in revenues. Both adjusted earnings for the quarter and quarterly revenues also topped analysts' expectations. However, the company issued weak earnings and sales growth outlook for fiscal 2022. Bentley Motors, owned by German automaker Volkswagen AG, announced plans to develop its first-ever Battery-Powered Electric Vehicle or BEV in 2025. The British luxury carmaker also plans investment of around 2.5 billion pounds or $3.4 billion in sustainability over the next ten years. The company will develop and build the new vehicles in the UK plant in Crewe.
Follow RTT